A first in human study of the new oral selective estrogen receptor degrader AZD9496 for HR+/HER2- advanced breast cancer.

CONCLUSIONS:  AZD9496 is well tolerated with an acceptable safety profile, showing evidence of prolonged disease stabilization in heavily pre-treated patients with ER+/HER2- advanced breast cancer.
PMID: 29440181 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 13, 2018 Category: Cancer & Oncology Authors: Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, Hoch M, Klinowska T, Lindemann JPO, Morgan S, Schiavon G, Weir HM, Im SA Tags: Clin Cancer Res Source Type: research